Stock Analysis

China Medical System Holdings Full Year 2022 Earnings: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021)

Source: Shutterstock

China Medical System Holdings (HKG:867) Full Year 2022 Results

Key Financial Results

  • Revenue: CN¥9.15b (up 9.8% from FY 2021).
  • Net income: CN¥3.26b (up 8.0% from FY 2021).
  • Profit margin: 36% (in line with FY 2021).
  • EPS: CN¥1.33 (up from CN¥1.22 in FY 2021).
SEHK:867 Earnings and Revenue Growth March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Medical System Holdings Earnings Insights

Looking ahead, revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 3.8% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of China Medical System Holdings' balance sheet and an in-depth analysis of the company's financial position.

Valuation is complex, but we're helping make it simple.

Find out whether China Medical System Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis